A detailed history of Burleson & Company, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Burleson & Company, LLC holds 540 shares of BIIB stock, worth $123,157. This represents 0.04% of its overall portfolio holdings.

Number of Shares
540
Previous 540 -0.0%
Holding current value
$123,157
Previous $144,000 3.47%
% of portfolio
0.04%
Previous 0.03%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 17, 2022

SELL
$194.69 - $268.46 $2,725 - $3,758
-14 Reduced 2.53%
540 $144,000
Q2 2022

Jul 13, 2022

BUY
$187.54 - $223.02 $2,625 - $3,122
14 Added 2.59%
554 $113,000
Q1 2021

May 12, 2021

BUY
$242.95 - $284.63 $131,193 - $153,700
540 New
540 $151,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $32.8B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Burleson & Company, LLC Portfolio

Follow Burleson & Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Burleson & Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Burleson & Company, LLC with notifications on news.